Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.311,63 +237,65 (+0,62%) EUR/USD
1,0778 -0,0006 (-0,05%) Bitcoin EUR
58.369,82 +1.257,42 (+2,20%) CMC Crypto 200
1.350,03 +49,93 (+3,84%)
ProMIS Neurosciences, Inc. (PMN)
| Chiusura precedente | 1,9200 |
| Aperto | 1,8000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,7400 - 1,8600 |
| Intervallo di 52 settimane | 0,9500 - 8,9500 |
| Volume | |
| Media Volume | 16.691 |
| Capitalizzazione | 33,94M |
| Beta (5 anni mensile) | 0,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,0700 |
| Prossima data utili | 06 mar 2024 - 11 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,75 |
GlobeNewswireProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyondTORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple sys
- GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Offi
- GlobeNewswire
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple syste
